By Bryan A. Wolf, MD, PhD, Chief Scientific Officer and Director of the Research Institute
Every space flight mission requires a carefully planned trajectory, and similarly the national Cancer Moonshot initiative needed a scientific roadmap to reach its ambitions of accelerating the prevention, diagnosis, and treatment of cancer to make a decade of progress in the next five years. In September,
The Felix Lab aims to understand the pathobiology of leukemias with KMT2A (MLL) translocations in order to discover better treatments and preventative approaches. These leukemias have a poor prognosis and they primarily afflict infants and young children or occur as a complication of TOP2 poison chemotherapies used for anti-cancer treatment. The studies use molecular, biochemical, cellular and in vivo methods.